 Adjuvant topical chemotherapy versus immunotherapy primary superficial transitional cell carcinoma bladder prospective study efficacy ethoglucid keyhole-limpet haemocyanin KLH recurrent tumours transurethral resection primary superficial transitional cell carcinoma bladder Patients ethoglucid solution weekly weeks year Patients KLH mg KLH bladder instillations mg weeks monthly year recurrence rates disease-free intervals tumour progression rates end-point study progression stage grade recurrence observation period minimum length follow-up year recurrence rates mean disease-free intervals progression rates groups significant differences